Payment overview · 2025
General Payments
$380.33
21 reported records · 10 companies
Healthcare provider profile · identity verified
Richard A Savell, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ALCOA, TN · NPI 1164475513
Verified facts
What the public records show
CMS Open Payments records show Richard A Savell, M.D. received $380.33 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $81.73 | 21.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.24 | 17.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.04 | 16.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.73 | 14.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.96 | 7.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.83 | 7.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.01 | 4.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.51 | 4.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.77 | 3.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.51 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $380.33 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $67.86 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.91 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.91 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.02 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.02 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.96 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.96 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 249 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
249 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
249 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 453 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 394 | 88 |
| Lisinopril | Lisinopril | 374 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 83 |
| Potassium Chloride | Potassium Chloride | 271 | 62 |
| Omeprazole | Omeprazole | 258 | 70 |
| Montelukast Sodium | Montelukast Sodium | 251 | 53 |
| Eliquis | Apixaban | 249 | 45 |
| Furosemide | Furosemide | 222 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 215 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 63 |
| Gabapentin | Gabapentin | 208 | 48 |
| Alprazolam | Alprazolam | 192 | 55 |
| Ezetimibe | Ezetimibe | 188 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 43 |
| Clonazepam | Clonazepam | 142 | 20 |
| Pregabalin | Pregabalin | 141 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 140 | 42 |
| Ozempic | Semaglutide | 139 | 24 |
| Irbesartan | Irbesartan | 129 | 31 |
| Losartan Potassium | Losartan Potassium | 129 | 41 |
| Valsartan | Valsartan | 126 | 36 |
| Meloxicam | Meloxicam | 116 | 43 |
| Tramadol Hcl | Tramadol Hcl | 116 | 36 |
| Spironolactone | Spironolactone | 111 | 29 |
| Metformin Hcl Er | Metformin Hcl | 107 | 32 |
| Celecoxib | Celecoxib | 106 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 33 |
| Simvastatin | Simvastatin | 105 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 27 |
| Methylprednisolone | Methylprednisolone | 99 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 25 |
| Metformin Hcl | Metformin Hcl | 96 | 24 |
| Baclofen | Baclofen | 94 | 29 |
| Glimepiride | Glimepiride | 94 | 23 |
| Lovastatin | Lovastatin | 92 | 19 |
| Trazodone Hcl | Trazodone Hcl | 87 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 21 |
| Famotidine | Famotidine | 76 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 14 |
| Carvedilol | Carvedilol | 61 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 28 |
| Buspirone Hcl | Buspirone Hcl | 52 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 13 |
| Atenolol | Atenolol | 48 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 48 | 11 |
| Mirtazapine | Mirtazapine | 48 | 15 |
| Mounjaro | Tirzepatide | 48 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 13 |
| Allopurinol | Allopurinol | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 12 |
| Nystatin | Nystatin | 41 | 15 |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 11 |
| Amoxicillin | Amoxicillin | 38 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 14 |
| Fluconazole | Fluconazole | 34 | 20 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | 11 |
| Bupropion Xl | Bupropion Hcl | 33 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Lactulose | Lactulose | 33 | suppressed |
| Prednisone | Prednisone | 33 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 23 |
| Eszopiclone | Eszopiclone | 32 | 12 |
| Meclizine Hcl | Meclizine Hcl | 32 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | 11 |
| Felodipine Er | Felodipine | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 15 |
| Ondansetron Odt | Ondansetron | 31 | 14 |
| Azithromycin | Azithromycin | 30 | 26 |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Nabumetone | Nabumetone | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 15 |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 11 |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $380.33 · 21 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, ELIQUIS, FARXIGA, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VAXNEUVANCE, Veozah, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error